$CATL

DeepSeek leads $400 million funding round for ex-Tencent scientist's robot AI startup

DeepSeek invested $20.8 million in Unitree Robotics' IPO, part of a broader $12 billion funding round. Unitree, valued at $9 billion, is China's first mainland-listed humanoid robot maker. The partnership aims to advance embodied AI, with DeepSeek focusing on model-training and Unitree on robotics.

Original reporting
Published Oct 12, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 12:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DeepSeek leads $400 million funding round for ex-Tencent scientist's robot AI startup — source image
Decision brief

The 30-second read

$CATLNeutralLow
01

Why it matters

The disclosed IPO investment amount and the reported larger funding round suggest capital is flowing toward robotics integration. However, the article does not provide a direct, tradable US-listed ticker for DeepSeek or Unitree, limiting immediate execution for US traders.

02

Market read

Traders may treat this as incremental confirmation that embodied-AI partnerships are becoming a funding priority, but the piece lacks a clear US-listed ticker catalyst.

03

What to watch

Key missing details include the actual size of CATL and Tencent commitments, Unitree’s post-IPO demand trajectory, and whether DeepSeek’s robotics model progress is measurable beyond partnership framing.

Relevance 4/10Novelty 4/10Timing: today

Background

DeepSeek is characterized as an open-weight LLM lab expanding into embodied AI via an investment in Unitree Robotics and a reciprocal procurement pact.

Company-level read

Ticker impact

$CATLNeutralLow confidence
Context

The article says Bloomberg reported DeepSeek was close to a new funding round backed by Tencent and battery giant CATL.

Expected impact

No clear directional call for CATL based on the article alone; any move would depend on deal size and market interpretation not provided here.

Evidence & confidence

CATL is mentioned as a reported backer, but the article lacks deal terms, stake size, or CATL-specific operational consequences.

Market effects

Reinforces a shift from chatbot-only competition toward embodied-AI, potentially increasing investor focus on robotics supply chains and model-to-robot integration.

Highlights Hangzhou’s AI and robotics cluster dynamic, which may attract additional capital and partnerships in the region.

Signals intensifying China competition in robotics-enabled AI, which can influence global sentiment toward embodied-AI investment cycles.

Counterpoint

The article may overstate strategic certainty: procurement priority does not guarantee revenue scale, and funding-round proximity can change before closing.

Key entities

  • DeepSeek

    AI lab investing in Unitree Robotics and reportedly pursuing a large new funding round backed by Tencent and CATL.

  • Unitree Robotics

    Humanoid robot maker that priced a Shanghai IPO and entered a procurement pact with DeepSeek.

  • Tencent

    Reported backer of DeepSeek’s new funding round.

  • CATL

    Reported backer of DeepSeek’s new funding round.

  • Manycore

    Spatial-intelligence company mentioned as part of the Hangzhou startup cluster.

Related articles

$XPEVMed

E-Week Review | CATL's 6.18 Billion Yuan Dividend Implemented; XPENG Shifts to Double Shifts to Ramp Up MONA L03 Capacity

EV market updates include XPeng shifting to double shifts to ramp MONA L03 output, with global launch pricing of 123,800 to 156,800 yuan and first-hour orders above 46,859 units. Leapmotor said its A10 reached 100,000 mass-produced units in 135 days. NIO reported 120 million cumulative swaps and the first batch of fifth-gen stations. CATL (300750) announced a 2024 interim dividend of 14.11 yuan per 10 shares, totaling about 6.18 billion yuan.

$GMABHigh

Genmab’s petosemtamab trial cuts death risk by 50% in cancer

Genmab A/S (GMAB) reported that its Phase 3 trial for petosemtamab met primary endpoints, reducing death risk by 50% in head and neck cancer patients. The combination therapy showed significant improvements in overall survival and response rates, with a hazard ratio of 0.50 and an objective response rate odds ratio of 3.17. The company plans regulatory submissions and further trial evaluations. Head and neck squamous cell carcinoma is the seventh most common cancer globally.

$MLYSMedAI 8/10

Mineralys Reports Phase 2 Lorundrostat Data In Chronic Kidney Disease

Mineralys Therapeutics (MLYS) reported Phase 2 trial results for Lorundrostat in chronic kidney disease patients, showing significant blood pressure reduction and kidney damage markers improvement. The drug is being evaluated for high blood pressure and related conditions. MLYS stock is currently at $21.09, down 0.21%.

$ADSEMed

ADS-TEC Energy receives permit approval for 1GW storage plant

ADS-TEC Energy (NASDAQ:ADSE) received permit approval for a 1GW battery storage plant in Germany, with a €1B investment expected. The company plans to sell a majority stake but remain a long-term partner. The facility, using ADS-TEC's proprietary technology, aims for a 2029 grid connection and could generate €150,000-€250,000 per MW annually, though not as a forecast.